a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC). 2025 ASCO GI. Abstract TPS507.
[6] Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014 Jul 1;32(19):2039-49. [7] Thuss-Patience PC, ...
[5]Hyung J, Kim HD, Ryu MH, et al. GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-Assessment for Initially HER2 Negative Advanced Gastric Cancer Patients After Progression on First-Line Treatment. Cancer Res Treat. 2...
[14]Shen L, Chen P, Lu J, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma ...
Janjigian在Nature上发表题为The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer 的文章,招募了434位HER2呈阳性,并患有胃肠道恶性肿瘤的病人,以随机双盲原则,进行PD-1抗体药物与曲妥珠单抗和化疗联合用药(clinicaltrials.gov, NCT03615326),并发现此种干预方式相比较传统的...
1 Indeed, the identification of HER2 status as a predictor of both prognosis and response to anti- HER2 drug trastuzumab changes now both the medical practice and the design of future gastric cancer clinical trials. The European Medicines Agency approved trastuzumab use for gastric cancer patients ...
[15]Shen L, Chen P, Lu J, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY...
[3] Shitara K, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):827-836. [4] Kabraji S, et al. Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brai...
[16]Shitara K Bang YJ,Iwasa S,et al.Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.N Engl J Med 2020;382:2419-2430. [17]Updated analysis of DESTINY-Gastric02:A phase II single-arm trial of trastuzumab deruxtecan(T-DXd)in western patients(Pts)with HER2-positive...
2023年8月16日，浙江大学医学院附属第一医院肿瘤外科滕理送教授和浙江大学基础医学院免疫研究所周全研究员团队在Advanced Science上在线发表了题为Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis的研究论文。该...